Common Contracts
2 similar null contracts by Cytori Therapeutics, Inc., Northern Oil & Gas, Inc.
6,500,000 Shares NORTHERN OIL AND GAS, INC. Common Stock PLACEMENT AGENCY AGREEMENTNorthern Oil & Gas, Inc. • October 30th, 2009 • Crude petroleum & natural gas • New York
Northern Oil and Gas, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated in this Placement Agency Agreement (this “Agreement”) and the Subscription Agreements in the form of Exhibit A attached hereto (the “Subscription Agreements”) entered into with the investors identified therein (each, an “Investor” and collectively, the “Investors”), to issue and sell up to an aggregate of 6,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The Company hereby confirms its several agreements with Canaccord Adams Inc. (“Canaccord”) and FIG Partners, LLC (“FIG”), as set forth below. Canaccord is referred to as the “Lead Placement Agent” and FIG is referred to as the “Co-Placement Agent;” and collectively, Canaccord and FIG are referred to as to the “Placement Agents.” The Shares are more fully described in the Prospectus (as defined below).
4,771,174 Shares Warrants to Purchase 6,679,644 Shares CYTORI THERAPEUTICS, INC. Common Stock PLACEMENT AGENCY AGREEMENTCytori Therapeutics, Inc. • March 10th, 2009 • Surgical & medical instruments & apparatus • New York
Cytori Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to certain investors located by you (each an “Investor” and, collectively, the “Investors”), (i) up to 4,771,174 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and (ii) warrants to purchase up to 6,679,644 shares of Common Stock (the “Warrants” and together with the Shares, the “Securities”). The shares of Common Stock issuable upon exercise of the Warrants are hereinafter referred to as the “Warrant Shares”. The Company desires to engage Piper Jaffray & Co. as its exclusive placement agent (the “Placement Agent”) in connection with such issuance and sale. The Securities are more fully described in the Registration Statement (as hereinafter defined).
